In a little-noticed announcement, Health Canada in October 2017 signaled its intention to raise the fees that drug makers will have to pay when they want to get a new medication on the market.

These user fees currently fund about 50 percent of Health Canada’s operating budget for regulating prescription drugs. Health Canada wants to increase that to 90 percent. In addition, it will rebate 25 percent of that fee if it fails to review new drug applications within an established period of time.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I have been buying brand name drugs from Canada for many years. I have never had a problem with the brand name manufacturers. The cost of my Synthyroid, Symbacort, Ventolin, Retin A in Canada equal to the same inthe USA is at least half the price there. You ought to be worried about the generic drugs in India as they often change their compounds, the facilities are dirty and contaminated and there is very little supervision and monitoring by USDA but physicians continue to subscribe them as many drug plans will not pay for name brands. Screw citizens of US. What are the poor going to do?

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy